Merck Patent Gmbh

Rolf Bruns

Josef Straub

Ilhan Celik

Rita Laeufle

Giorgio Massimini

Methods of treatment of colorectal cancer can include the administration of the anti-alpha-v integrin (receptor) antibody Abituzumab. Preferably, the methods of treating colorectal cancer can include treating Stage II-IV colorectal cancer, metastatic colorectal cancer, left-sided colorectal cancer and/or left-sided metastatic colorectal cancer, involving the administration of said Abituzumab to patients in need thereof. Abituzumab is also useful for the manufacture of a medicament for treating colorectal cancer, preferably colorectal cancer as defined herein. Abituzumab is further useful for the manufacture of a medicament for treating colorectal cancer in combination with suitable targeted therapy concepts, such as growth factor or growth factor receptor targeting monoclonal antibodies, and/or chemotherapy.

Growing community of inventors

Darmstadt, Germany

Rolf Bruns